Case study on Type 2 diabetes management: implementation of a DPP-4 inhibitor switch strategy across a primary care network
This advertorial has been commissioned and developed by Takeda UK Ltd.
Supported by an arm’s-length educational grant from Mylan.
Real-world evidence in the management of type 2 diabetes: switching from other DPP‑4 inhibitors to alogliptin (Vipidia®)
This promotional educational webinar has been organised and funded by Takeda UK Ltd. See bottom of page for full disclaimer.
Guidelines identified a need for clinical guidance in a specific area and approached Mylan for an educational grant to support the development of a working party guideline. This working party guideline was developed by Guidelines, and the Chair and members of the group were chosen by and convened by ...